Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

Anthony V. D’Amico, James W. Denham, Juanita Crook, +9

Journal of Clinical Oncology

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

James W. Denham, Allison Steigler, David S. Lamb, +10

The Lancet Oncology

UrologyGenitourinary CancerMedicine10-Year DataAdvanced Prostate Cancer +4

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

James W. Denham, Allison Steigler, David S. Lamb, +15

The Lancet Oncology

UrologyRadiation MedicineRadiation TherapyMedicineShort-term Androgen Deprivation +4

Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group

Mark Sidhom, Andrew Kneebone, Margot Lehman, +5

Radiotherapy and Oncology

UrologySurgical OncologyGenitourinary CancerMedicineSurgery +5

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

James W. Denham, David Joseph, David S. Lamb, +14

The Lancet Oncology

Zoledronic AcidUrologyTrog 03.04Radiation TherapyMedicine +4

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

James W. Denham, David Joseph, David S. Lamb, +14

The Lancet Oncology

Zoledronic AcidUrologyRadiation MedicineTrog 03.04Radiation Therapy +5

Direct 2-Arm Comparison Shows Benefit of High-Dose-Rate Brachytherapy Boost vs External Beam Radiation Therapy Alone for Prostate Cancer

Richard Khor, Gillian Duchesne, Keen‐Hun Tai, +5

International Journal of Radiation Oncology*Biology*Physics

Radiation MedicineRadiation TherapyMedicineBrachytherapyOncology +4

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

James W. Denham, Allison Steigler, Chantelle Wilcox, +10

The Lancet Oncology

UrologyGenitourinary CancerMedicineProstatic DiseaseOncology +4

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

James W. Denham, Allison Steigler, David Joseph, +19

Radiotherapy and Oncology

UrologyTrog 03.04Radiation TherapyMedicineRadar Trial +5

Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial

Paul Keall, Doan Trang Nguyen, Ricky O’Brien, +22

International Journal of Radiation Oncology*Biology*Physics

Spark TrialEngineeringMedical ImagingBiomedical ImagingBrachytherapy +10